Yandex metrika counter
Gilead to buy Arcellx in $7.8B deal
Source: Reuters

Gilead Sciences said on Monday it will acquire cancer therapy developer Arcellx in a deal valuing the company at an implied equity value of $7.8 billion.

Under the agreement, Gilead will pay $115 per share in cash at closing, along with one contingent value right worth $5 per share, News.Az reports, citing Reuters.

The offer represents an 87% premium to Arcellx’s last closing price.

Following the announcement, Arcellx shares surged 77.8% to $113.99 in premarket trading.


News.Az 

By Nijat Babayev

Similar news

Archive

Prev Next
Su Mo Tu We Th Fr Sa
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31